Supplementary material

Effectiveness of disease-modifying treatment on spinal cord lesion formation in relapse-onset multiple sclerosis. An MSBase registry study.

Daniel Kreiter, Tomas Kalincik, Raymond Hupperts, Francesco Patti, Daniele Spitaleri, Matteo Foschi, Andrea Surcinelli, Davide Maimone, Bassem Yamout, Samia J. Khoury, Jeannette Lechner-Scott, Serkan Ozakbas, Oliver Gerlach on behalf of the MSBase Study Group

Corresponding Author

Daniel Kreiter Academic MS center Zuyd, Department of Neurology Zuyderland MC, Sittard-Geleen, The Netherlands <u>d.kreiter@zuyderland.nl</u>

Published in CNS Drugs


Table of contents

- S1 Data quality procedure
- S2 Propensity score matching
- S3 Country of treatment of matched patients
- S4 Patient characteristics and treatments for sensitivity analysis (broad caliper, 80% cutoff)
- S5 List of contributors

S1 - Data quality procedure


- Duplicate patients were removed.
- Patients with missing date of birth, date of first symptoms and date of diagnosis were excluded.
- Patients with onset dates after MSBase data extraction were removed.
- A logical MS course (e.g. clinically isolated syndrome, relapsing- remitting MS, secondary progressive MS) was assured.
- MRI investigations with insufficient data (e.g. missing information on whether there were new lesions) were removed.
- Duplicate MS relapses, EDSS scores, MRI investigations, visits and treatment entries were merged
- EDSS scores outside the possible EDSS range were removed.
- Relapses occurring within 30 days of each other were merged.
- MS disease modifying therapies were identified and labelled.
- Invalid treatment entries were removed (e.g. start date > end date, initiation after the MSBase data extract date).

S2 - Propensity score matching



Covariate balance before and after matching in the primary analysis.

Distribution of Propensity Scores



Propensity score matching of hDMT and IDMT groups in the primary analysis

	Unma	atched	Matched				
Characteristic	hDMT , N = 94 ¹	IDMT , N = 783 ¹	SMD ²	hDMT , N = 77 ¹	IDMT , N = 184 ¹	SMD ²	
Country							
AU	17 (18%)	48 (6.1%)	0.31	13 (17%)	28 (15%)	0.12	
BE	0 (0%)	17 (2.2%)	0.16	0 (0%)	0 (0%)	0.00	
BR	0 (0%)	2 (0.3%)	0.05	0 (0%)	0 (0%)	0.00	
CA	3 (3.2%)	21 (2.7%)	0.03	3 (3.9%)	8 (4.3%)	0.00	
CU	0 (0%)	1 (0.1%)	0.04	0 (0%)	0 (0%)	0.00	
ES	2 (2.1%)	17 (2.2%)	0.00	2 (2.6%)	7 (3.8%)	0.01	
IN	0 (0%)	1 (0.1%)	0.04	0 (0%)	0 (0%)	0.00	
IT	64 (68%)	256 (33%)	0.76	52 (68%)	115 (63%)	0.09	
KW	0 (0%)	2 (0.3%)	0.05	0 (0%)	0 (0%)	0.00	
LB	3 (3.2%)	51 (6.5%)	0.19	3 (3.9%)	10 (5.4%)	0.04	
OM	1 (1.1%)	3 (0.4%)	0.07	0 (0%)	2 (1.1%)	0.09	
PT	0 (0%)	3 (0.4%)	0.07	0 (0%)	0 (0%)	0.00	
RO	0 (0%)	4 (0.5%)	0.08	0 (0%)	0 (0%)	0.00	
TN	0 (0%)	9 (1.1%)	0.11	0 (0%)	0 (0%)	0.00	
TR	4 (4.3%)	346 (44%)	1.98	4 (5.2%)	14 (7.6%)	0.03	
US	0 (0%)	2 (0.3%)	0.05	0 (0%)	0 (0%)	0.00	

S3 - Country of treatment of matched patients

¹Median (IQR); n (%); Mean (SD)

²Standardized mean difference

AU = Australia, BE = Belgium, BR = Brazil, CA = Canada, CU = Cuba, ES = Spain, IN = India, IT = Italy, KW = Kuwait, LB = Libanon, OM = Oman, PT = Portugal, RO = Romania, TN = Tunisia, TR = Turkey, US = United States

S4 - Patient characteristics and treatments for sensitivity analysis (broad caliper, 80% cutoff)

Characteristics of patients included in this sensitivity analysis

	Unmatched			Matched				
Characteristic	hDMT , N = 116 ¹	IDMT , N = 917 ¹	SMD ²	hDMT , N = 113 ¹	IDMT , N = 441 ¹	SMD ²		
Age	37 (29, 45)	32 (26, 40)	0.28	37 (29, 46)	35 (28, 42)	0.04		
Gender								
F	78 (67%)	650 (71%)	0.08	76 (67%)	303 (69%)	0.06		
М	38 (33%)	267 (29%)	0.08	37 (33%)	138 (31%)	0.06		
EDSS	2.5 (2.0, 4.0)	2.0 (1.0, 2.5)	0.71	2.5 (2.0, 4.0)	2.0 (1.5, 3.0)	0.08		
Baseline brain lesions								
0	3 (2.6%)	9 (1.0%)	0.10	2 (1.8%)	6 (1.4%)	0.01		
1-2	1 (0.9%)	24 (2.6%)	0.19	1 (0.9%)	7 (1.6%)	0.03		
3-8	10 (8.6%)	224 (24%)	0.56	10 (8.8%)	91 (21%)	0.07		
9+	102 (88%)	660 (72%)	0.49	100 (88%)	337 (76%)	0.05		
Baseline spinal cord lesions	3.0 (1.0, 5.3)	1.0 (0.0, 2.0)	0.67	3.0 (1.0, 5.0)	2.0 (1.0, 3.0)	0.07		
Relapses in past year	1.0 (1.0, 2.0)	1.0 (1.0, 1.0)	0.38	1.0 (1.0, 2.0)	1.0 (1.0, 2.0)	0.07		
Relapses in past 2 years	2.0 (1.0, 2.0)	1.0 (1.0, 2.0)	0.32	2.0 (1.0, 2.0)	1.0 (1.0, 2.0)	0.08		
Years since first symptoms	5.4 (7.1)	3.2 (5.2)	0.31	5.5 (7.2)	3.8 (6.2)	0.06		
Follow-up in years	2.5 (1.6, 3.4)	3.1 (1.6, 5.9)		2.5 (1.6, 3.4)	3.3 (1.7, 6.2)			
Country								
AU	22 (19%)	60 (6.5%)	0.32	21 (19%)	55 (12%)	0.02		

	Unma	Matched				
Characteristic	hDMT , N = 116 ¹	IDMT , N = 917 ¹	SMD ²	hDMT , N = 113 ¹	IDMT , N = 441 ¹	SMD ²
BE	0 (0%)	18 (2.0%)	0.15	0 (0%)	0 (0%)	0.00
BR	0 (0%)	2 (0.2%)	0.05	0 (0%)	0 (0%)	0.00
CA	3 (2.6%)	25 (2.7%)	0.01	3 (2.7%)	16 (3.6%)	0.02
CU	0 (0%)	2 (0.2%)	0.05	0 (0%)	0 (0%)	0.00
EG	0 (0%)	1 (0.1%)	0.04	0 (0%)	0 (0%)	0.00
ES	2 (1.7%)	23 (2.5%)	0.06	2 (1.8%)	14 (3.2%)	0.04
GR	0 (0%)	2 (0.2%)	0.05	0 (0%)	0 (0%)	0.00
IN	2 (1.7%)	1 (0.1%)	0.12	2 (1.8%)	1 (0.2%)	0.07
IT	76 (66%)	300 (33%)	0.69	74 (65%)	261 (59%)	0.00
KW	0 (0%)	2 (0.2%)	0.05	0 (0%)	0 (0%)	0.00
LB	5 (4.3%)	69 (7.5%)	0.16	5 (4.4%)	38 (8.6%)	0.01
ОМ	1 (0.9%)	3 (0.3%)	0.06	1 (0.9%)	3 (0.7%)	0.02
PT	0 (0%)	4 (0.4%)	0.07	0 (0%)	0 (0%)	0.00
RO	0 (0%)	5 (0.5%)	0.08	0 (0%)	0 (0%)	0.00
TN	0 (0%)	10 (1.1%)	0.11	0 (0%)	0 (0%)	0.00
TR	5 (4.3%)	387 (42%)	1.87	5 (4.4%)	53 (12%)	0.01
US	0 (0%)	3 (0.3%)	0.06	0 (0%)	0 (0%)	0.00

¹Median (IQR); n (%); Mean (SD)

²Standardized mean difference

BE = Belgium, BR = Brazil, CA = Canada, CU = Cuba, EG = Egypt, ES = Spain, GR = Greece, IN = India, IT = Italy, KW = Kuwait, LB = Libanon, OM = Oman, PT = Portugal, RO = Romania, TN = Tunisia, TR = Turkey, US = United States

S5 – List of contributors

From Brain and Mind Centre, Sydney, Australia, Michael Barnett From Barwon Health, University Hospital Geelong, Geelong, Australia, Cameron Shaw From Monash University, Clayton, Australia, Nevin John From Box Hill Hospital, Box Hill, Australia, Katherine Buzzard From Box Hill Hospital, Melbourne, Australia, Olga Skibina From Westmead Hospital, Sydney, Australia, Justin Garber From University of Queensland, Brisbane, Australia, Pamela McCombe From Royal Hobart Hospital, Hobart, Australia, Bruce Taylor From The Alfred Hospital, Melbourne, Australia, Anneke van der Walt From The Alfred Hospital, Melbourne, Australia, Helmut Butzkueven From Royal Brisbane and Women's Hospital, Brisbane, Australia, Pamela McCombe From CISSS Chaudière-Appalache, Levis, Canada, Pierre Grammond From Neuro Rive-Sud, Quebec, Canada, Francois Grand'Maison From Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada, Emmanuelle Lapointe From Galdakao-Usansolo University Hospital, Osakidetza-Basque Health Service, Galdakao, Spain, Jose Luis Sanchez-Menoyo From Hospital Universitari MútuaTerrassa, Barcelona, Spain, Sarah Besora From Università di Bologna, Bologna, Italia, Alessandra Lugaresi From University G. d'Annunzio, Chieti, Italy, Marco Onofri From University of Florence, Florence, Italy, Maria Pia Amato From Royal Hospital, Muscat, Oman, Jabir Alkhaboori From Sultan Qaboos University, Al-Khodh, Oman, Abdullah Al-Asmi From KTU Medical Faculty Farabi Hospital, Trabzon, Turkey, Cavit Boz From Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey, Aysun Soysal From Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey, Recai Turkoglu

Administrative support was provided by:

Carolyn Tran, Membership Coordinator of the MSBase Foundation Ltd

Cynthia Tang, Study Coordinator and Scientific Secretary of the MSBase Foundation Ltd